Targeting the" vicious cycle" of cancer-induced bone disease with TRAIL and bisphosphonates

用 TRAIL 和双磷酸盐治疗癌症引起的骨病的“恶性循环”

基本信息

  • 批准号:
    nhmrc : 453644
  • 负责人:
  • 金额:
    $ 29.59万
  • 依托单位:
  • 依托单位国家:
    澳大利亚
  • 项目类别:
    NHMRC Project Grants
  • 财政年份:
    2007
  • 资助国家:
    澳大利亚
  • 起止时间:
    2007-01-01 至 2009-12-31
  • 项目状态:
    已结题

项目摘要

The most serious clinical problem with patients with many forms of solid tumours is metastasis to bone, which leads to potentially debilitating complications that can cause erosion of the patient's quality of life, and eventually death. Unfortunately, bony metastases usually occur before pre-emptive treatments can be applied to prevent it. We have recently shown that recombinant soluble TRAIL is a potent anticancer agent that prevents cancer-induced bone destruction in a mouse model by directly targeting cancer cells within bone, and with no evidence of toxic side effects to normal tissues. Death receptor targeting by TRAIL, and bisphosphonates induce cancer cell apoptosis through different but overlapping signaling pathways. Therefore, combination of the two approaches may facilitate killing of tumour cells that resist death induction through either one of the pathways. Combination therapy may also reduce the probability of acquired resistance to either therapy. We propose that a combinatorial approach, using bisphosphonates to selectively target osteoclasts and TRAIL to selectively target cancer cells, would be an ideal therapeutic and safe approach to delay, slow or completely eliminate growth of cancer within bone.
对于患有多种形式实体瘤的患者来说,最严重的临床问题是转移到骨骼,这会导致潜在的衰弱性并发症,从而影响患者的生活质量,最终导致死亡。不幸的是,骨转移通常发生在预防性治疗之前。我们最近的研究表明,重组可溶性TRAIL是一种有效的抗癌剂,通过直接靶向骨内的癌细胞,在小鼠模型中防止癌症引起的骨破坏,并且没有证据表明对正常组织有毒副作用。TRAIL和双膦酸盐通过不同但重叠的信号通路诱导癌细胞凋亡。因此,两种方法的结合可能有助于通过其中一种途径杀死抵抗死亡诱导的肿瘤细胞。联合治疗也可以减少对任何一种治疗产生获得性耐药的可能性。我们提出一种组合方法,使用双膦酸盐选择性靶向破骨细胞和TRAIL选择性靶向癌细胞,将是一种理想的治疗和安全的方法,可以延迟、减缓或完全消除骨内癌症的生长。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Prof Andreas Evdokiou其他文献

Prof Andreas Evdokiou的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Prof Andreas Evdokiou', 18)}}的其他基金

Vitamin E-bisphosphonate conjugates: A new therapeutic approach targeting pathological bone loss associated with osteoporosis
维生素 E-二磷酸盐结合物:一种针对与骨质疏松症相关的病理性骨丢失的新治疗方法
  • 批准号:
    nhmrc : 1050694
  • 财政年份:
    2013
  • 资助金额:
    $ 29.59万
  • 项目类别:
    Project Grants
Novel therapeutic approaches for the treatment of skeletal malignancies
治疗骨骼恶性肿瘤的新方法
  • 批准号:
    nhmrc : 627015
  • 财政年份:
    2010
  • 资助金额:
    $ 29.59万
  • 项目类别:
    Career Development Fellowships
Antitumour efficacy of TRAIL: an immunotherapeutic approach for the treatment of skeletal malignancies
TRAIL 的抗肿瘤功效:一种治疗骨骼恶性肿瘤的免疫治疗方法
  • 批准号:
    nhmrc : 565357
  • 财政年份:
    2009
  • 资助金额:
    $ 29.59万
  • 项目类别:
    NHMRC Project Grants
Use of TRAIL therapy to selectively kill bone tissue cancer cells whilst sparing normal cells
使用 TRAIL 疗法选择性杀死骨组织癌细胞,同时保留正常细胞
  • 批准号:
    nhmrc : 349359
  • 财政年份:
    2005
  • 资助金额:
    $ 29.59万
  • 项目类别:
    Career Development Fellowships

相似海外基金

Chromatin architecture disruption and the vicious cycle of aging.
染色质结构破坏和衰老的恶性循环。
  • 批准号:
    10901040
  • 财政年份:
    2023
  • 资助金额:
    $ 29.59万
  • 项目类别:
The elucidation of the cancer-fibroblast vicious cycle in the tumor microenvironment has revealed a critical mechanism underlying cancer progression and resistance to therapy.
肿瘤微环境中癌症-成纤维细胞恶性循环的阐明揭示了癌症进展和治疗耐药的关键机制。
  • 批准号:
    23K14556
  • 财政年份:
    2023
  • 资助金额:
    $ 29.59万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
HappierFeet-Disrupting the vicious cycle of healthcare decline in Diabetic Foot Ulceration through active prevention: The future of self-managed care
HappierFeet-通过积极预防打破糖尿病足溃疡医疗保健下降的恶性循环:自我管理护理的未来
  • 批准号:
    EP/W00366X/1
  • 财政年份:
    2021
  • 资助金额:
    $ 29.59万
  • 项目类别:
    Research Grant
A Stress-Induced Vicious Cycle In The Development of T1D
压力诱发 T1D 发展的恶性循环
  • 批准号:
    10653099
  • 财政年份:
    2020
  • 资助金额:
    $ 29.59万
  • 项目类别:
A Stress-Induced Vicious Cycle In The Development of T1D
压力诱发 T1D 发展的恶性循环
  • 批准号:
    10262964
  • 财政年份:
    2020
  • 资助金额:
    $ 29.59万
  • 项目类别:
A Stress-Induced Vicious Cycle In The Development of T1D
压力诱发 T1D 发展的恶性循环
  • 批准号:
    10440524
  • 财政年份:
    2020
  • 资助金额:
    $ 29.59万
  • 项目类别:
Evaluation and Disruption of Tau - GSK3β Vicious Cycle
Tau 的评估和破坏 - GSK3β 恶性循环
  • 批准号:
    10398663
  • 财政年份:
    2019
  • 资助金额:
    $ 29.59万
  • 项目类别:
Interrupting the Vicious Cycle of Obesity and Metabolic Syndrome
中断肥胖和代谢综合症的恶性循环
  • 批准号:
    9985360
  • 财政年份:
    2019
  • 资助金额:
    $ 29.59万
  • 项目类别:
Basic research on muscle loss and umami sensitivity disorder in the vicious cycle of frailty syndrome
衰弱综合征恶性循环中肌肉损失和鲜味敏感性障碍的基础研究
  • 批准号:
    19K11647
  • 财政年份:
    2019
  • 资助金额:
    $ 29.59万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Evaluation and Disruption of Tau - GSK3ò Vicious Cycle
Tau 的评估和破坏 - GSK3™ 恶性循环
  • 批准号:
    10237411
  • 财政年份:
    2019
  • 资助金额:
    $ 29.59万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了